InnoMedica is a Swiss pharmaceutical company focused on developing innovative medicines up to and including Phase II clinical development, based on its proprietary, patent-protected technology platform. By enabling the targeted delivery and controlled release of active pharmaceutical ingredients at their site of action, this approach aims to enhance therapeutic efficacy while improving tolerability. It forms the foundation of our programs in neurology — most notably the development of a therapy for the treatment of Parkinson’s disease.
The InnoMedica team combines experience with scientific expertise. Professionals work alongside scientists and emerging talents to explore new therapeutic pathways. This collaborative approach has led to developments such as our lead program for the treatment of Parkinson’s disease and a next-generation chemotherapy in oncology — programs that demonstrate the potential of our proprietary technology and pave the way for future Phase III partnerships.
In 2013, InnoMedica initiated its first clinical development project. Through the acquisition of the Japanese company YAMAZAKI-DDS Co., Ltd., InnoMedica gained access to a nanotechnology platform that had been researched and refined over many years and continues to form the foundation of our drug development activities. The objective has been to improve established therapies through advanced formulation technology.
Following rapid development progress and the establishment of GMP manufacturing capabilities in Marly, the oncology program entered clinical testing in 2018. Shortly thereafter, the neurological program advanced into clinical development, leading to the first treatment of a Parkinson’s patient within the NEON study in 2021.
Today, specialists across our sites in Marly and Bern contribute expertise spanning research and development, manufacturing, quality control and analytics, regulatory affairs, clinical research, finance, HR and communications. Supported by supply chain and IT functions, they collectively form the foundation of our mission: to bring innovative therapies to patients.
Learn more about Our Team.
